Clinical Trial Update: Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of sorafenib with the FOLFIRI regimen for second-line colorectal cancer after oxaliplatin failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Camptosar) (Irinotecan)
• Leucovorin (folinic acid) (folinic acid)
• Sorafenib (Nexavar) (Sorafenib)

Snippet

Sponsor: Fudan University | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN